In a previous study conducted by LoRusso and Iyadurai in 2017 (28), they reported a CMS patient with mutations in RAPSN, whose encoded protein acted to concentrate and anchor acetylcholine receptors in the postsynaptic membrane. The gene discussed is RAPSN; the disease is congenital myasthenic syndrome.